• Journal of Periodontal and Implant Science
• /
• v.19 no.2
• /
• pp.138.2-138.2
• /
• 1989

• Journal of Periodontal and Implant Science
• /
• v.21 no.1
• /
• pp.177.1-177.1
• /
• 1991

• Nuclear Medicine and Molecular Imaging
• /
• v.42 no.3
• /
• pp.185-191
• /
• 2008

While indirect targeting strategies using reporter-genes are taking center stage in current molecular imaging research, another vital strategy has long involved direct imaging of specific receptors using radiolabeled ligands. Recently, there is renewal of immense interest in this area with particular attention to the epidermal growth factor receptor (EGFR), a transmembrane glycoprotein critically involved in the regulation of many cellular functions and malignancies. Recently, two novel classes of EGFR-targeting anticancer drugs have entered clinical trials with great expectations. These are monoclonal antibodies such as cetuximab that target the extracellular domain, and small molecule tyrosine kinase inhibitors such as gefitinib (lressa) and erlotinib (Tarceva) that target the catalytic domain of the receptor. However, early results have showed disappointing survival benefits, disclosing a major challenge for this therapeutic strategy; namely, the need to identify tumors that are most likely to respond to the agents. To address this important clinical issue, several noninvasive imaging techniques are under investigation including radiolabeled probes based on small molecule tyrosine kinase inhibitors, anti-EGFR antibodies, and EGF peptides. This review describes the current status, limitations, and future prospects in the development of radiotracer methods for EGFR imaging.

• Microbiology and Biotechnology Letters
• /
• v.22 no.5
• /
• pp.477-484
• /
• 1994

Using a methylotrophic yeast Hansenula polymorpha, a heterologous gene expression and secretion system was developed for the production of hEGF(human Epidermal Growth Factor) which has been shown to promote epithelial cell proliferation and to inhibit gastric acid secretion. The hEGF gene was chemically synthesized according to the preferred codon usage in H. polymor- pha and expressed under the control of the strong and inducible methanol oxidase(MOX) promoter. The mating factor $\alpha$ pre-pro leader sequence of Saccharomyces cerevisiae was employed for hEGF to be secreted into the extracellular medium. This expression cassette was stably integrated into the host chromosomal DNA. Mature hEGF was efficiently expressed and secreted into the extracel- lular medium. About 24 mg/l of hEGF was detected in the cuture supernatant of a transformant with pA-EGF3 under the suboptimal culture conditions.

• Journal of Digestive Cancer Research
• /
• v.1 no.1
• /
• pp.24-28
• /
• 2013

The five-year survival for patients with gastric cancer improved only modestly over the last 50 years. So, several studies about molecular target chemotherapy were investigated. We reviewed about molecular target chemotherapy for advanced unresectable and metastatic gastric cancer, which has developed recently. EGFR (Epidermal growth factor receptor), HER (Human epidermal growth factor receptor), VEGF (Vascular endothelial growth factor receptor) can be the target of therapy for gastric cancer. Patients with advanced gastric adenocarcinoma who are potential candidates for trastuzumab should have their tumors assayed for the presence of HER2 overexpression utilizing tumor-specific criteria and/or gene amplification. We suggest the addition of trastuzumab to chemotherapy in patients with HER2-positive tumors (as defined by 3+ immunohistochemical staining or FISH positivity), as long as they do not have a contraindication to trastuzumab. Except for trastuzumab, we summarized several studies for molecular target agents which were not validated yet.

• Archives of Pharmacal Research
• /
• v.25 no.1
• /
• pp.71-76
• /
• 2002

Ginseng has been used as a traditional medicine with various therapeutic effects. However, it is still unknown which component of this plant is effective at promoting wound healing. Recently, ginsenoside $Rb_2$ has been reported to improve wound healing. In this study, to investigate the reported wound healing effect of the ginsenoside $Rb_2$, cell morphology and protein factors involved in epidermal formation were evaluated by immunshemical and immunoblotting analysis. $Rb_2$ stimulated epidermal cell proliferation, and the cell showed a 1.5-fold increase in thymidine uptake compared to the control (p<0.05, n=3). Futheremore $Rb_2$, was found to stimulate epidermis formation in a dose-dependent manner in raft culture, and to dose dependently enhance the expressions of protein factors related to cell proliferation, namely, epidermal growth factor and its receptor, fibronectin and its receptor, keratin 5/14, and collagenase 1 (p<0.05, n=3~9). It is believed that ginsenoside $Rb_2$, enhances epidermal cell proliferation by upregulating the expressions of these proliferation-related factors.

• Tuberculosis and Respiratory Diseases
• /
• v.79 no.4
• /
• pp.248-256
• /
• 2016

Somatic mutations that lead to hyperactivation of epidermal growth factor receptor (EGFR) signaling are detected in approximately 50% of lung adenocarcinoma in people from the Far East population and tyrosine kinase inhibitors are now the standard first line treatment for advanced disease. They have led to a doubling of progression-free survival and an increase in overall survival by more than 2 years. However, emergence of resistant clones has become the primary cause for treatment failure, and has created a new challenge in the daily management of patients with EGFR mutations. Identification of mechanisms leading to inhibitor resistance has led to new therapeutic modalities, some of which have now been adapted for patients with unsuccessful tyrosine kinase inhibitor treatment. In this review, we describe mechanisms of tyrosine kinase inhibitor resistance and the available strategies to overcoming resistance.

• The Korean Journal of Zoology
• /
• v.34 no.3
• /
• pp.410-419
• /
• 1991

마우스 악하선 배양세포의 DNA와 단백질 합성 및 epidermal growth factor(EGF) 분비에 미치는 isoproterenol(IPR)의 효과를 조사하였다. 마우스 악하선으로부터 분리되어 배양된 상피형세포의 DNA및 단백질 합성은 IRP에 의해 농도 의존적으로 현저하게 감소하였다. 이와는 달리 IPR처리 1시간 후에 IPR-처리 마우스로부터 얻은 혈청은 악하선 배양세포의 단백질 합성에는 별 영향을 미치지 못하였으나, DNA합성은 현저하게 증가시켰다. IPR에 의한 악하선 세포의 DNA 합성능의 감소는 propranolol에 의해 차단되지 않았으나 ascorbate에 의해서는 회복되었다. 악하선 배양세포의 DNA 및 단백질 합성을 저해한 IPR의 처리에 의해 배양세포의 EGF분비는 현저히 증가되었다. 이상과 같은 결과는 악하선 세포의 DNA 및 단백질 합성에 작용한 IPR의 효과는 beta-adrenoceptor의 흥분에 의한 것이라기 보다는 IPR로부터 유래된 free radical에 의한 세포독성에 기인함을 시사한다. 따라서 IPR의 생체내 투여에 의한 악하선의 비대화를 보고 한 기존의 결과는 IPR이 악하선에 직접 작용하여 유발된 것이 아닌 다른 경로를 통한 간접적인 효과로 판단될 수 있을 것이다.

• Archives of Pharmacal Research
• /
• v.26 no.8
• /
• pp.649-652
• /
• 2003

Polymeric nanoparticles composed of polystyrene (PS) as core and poly(methacrylic acid) (PMA) as corona were prepared by the dispersion copolymerization. The potential of the nanoparticles as carriers for recombinant human epidermal growth factor (EGF) was investigated. The nanoparticles showed monodispersity and good water-dispersibility. The loading content of EGF to the nanoparticles was very high due to electrostatic interaction between EGF and nanoparticles. EGF was released as a pseudo-zero order pattern after initial burst effect. The nanoparticles were sufficient for A431 cells proliferation.

• Medical Lasers
• /
• v.8 no.2
• /
• pp.94-96
• /
• 2019

Burns are one of the most extensive injuries of soft tissues as well as skin, occasionally resulting in extensive, deep wounds and death. Burn wounds can lead to severe physical and psychological distress because of excessive scarring and skin contractures. Treatment of burn wounds has always been a challenging problem and many different methods have been used to treat such injuries. We report here on treating a patient with a burn wound using 830-nm light emitting diode (LED) phototherapy combined with epidermal growth factor (EGF) solution. After five daily sessions of LED with EGF solution treatment, the patient demonstrated nearly complete improvement with no remarkable side effects. We suggest that LED phototherapy combined with EGF solution could be an effective and safe treatment option for treating burn wounds.